Vaccines nonprofit The Human Vaccines Project (HVP) on Thursday launched the COVID Vaccine Initiative (CVI) to help develop safe, effective, accessible vaccines for those most vulnerable to COVID-19.
The focus will be on accelerating vaccine development for older people and those living in low- and middle-income countries.
In partnership with scientists, vaccine developers, the Harvard T.H. Chan School of Public Health, FHI 360 and the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, HVP will conduct natural history and vaccine studies and will apply its methods in immune monitoring, systems biology and artificial intelligence to determine how to generate effective immunity in these vulnerable populations.
The CVI's Advocacy and Policy programme will serve as a forum for dissemination and synthesis of critical information and data relevant to accelerating vaccine development, and it will develop a roadmap to ensure that the major R&D challenges impeding the development of safe and effective SARS-CoV-2 vaccines are addressed.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government